[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"PerkinElmer Health Sciences, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":101},{"warningLetters":4,"total":100},[5,33,57,79],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2340,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022\">Calroy Health Sciences, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-07192023\">\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chen and Mr. Hoyt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Calroy Health Sciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14362 N Frank Lloyd Wright, Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636311\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen and Mr. Hoyt:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Arterosil product page at www.arterosil.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Under the “Patient Education” Tab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; &nbsp;and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chen and Mr. Hoyt\n\nCalroy Health Sciences, LLC\n\n14362 N Frank Lloyd Wright, Suite 1000\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636311\n\nDear Mr. Chen and Mr. Hoyt:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\n\nOn your Arterosil product page at www.arterosil.com:\n\n\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\n\n“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\n\n\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\n\nUnder the “Patient Education” Tab\n\n\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\n\n\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\n\n\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\n\n\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\n\n\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\n\nYour Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","Calroy Health Sciences, LLC","calroy-health-sciences-llc-636311-11142022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022","2026-10-26T08:08:10.528128+00:00","Warning Letter","Closed Out","2022-11-17","636311","Dietary SupplementsDrugs","2023-07-21","Mr. Chen and Mr. Hoyt","2026-08-20T01:25:36.732+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":34,"raw":35,"subject":12,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":24,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":39,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":20,"action_taken_date":56,"medical_device_id":20,"response_letter_date":20},3011,[36,37,38,39,40,13,41,13],"\u003Ctime datetime=\"2021-11-30T14:20:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-18T05:00:00Z\">11\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021\">Saffron Health Sciences\u003C\u002Fa>","Division of Human and Animal Food Operations East II","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-01182022\">\u003Ctime datetime=\"2022-02-15T05:00:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Song Gao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Saffron Health Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 Dexter Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>E Brunswick\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08816-2873\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #615429\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 18, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Gao;\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at&nbsp;\u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\u003C\u002Fli>\n\t\u003Cli>“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\u003C\u002Fli>\n\t\u003Cli>“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\u003C\u002Fli>\n\t\u003Cli>“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\u003C\u002Fli>\n\t\u003Cli>“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The neuroprotective effects of crocin against stroke is the focus of this article.”\u003C\u002Fli>\n\t\u003Cli>“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNF\u003Cspan>\u003Cspan>a\u003C\u002Fspan>\u003C\u002Fspan>), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\u003Cbr>\n&nbsp; &nbsp; o “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\u003Cbr>\n&nbsp; &nbsp; o “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\u003C\u002Fp>\n\n\u003Cp>From the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\u003C\u002Fli>\n\t\u003Cli>“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\u003C\u002Fli>\n\t\u003Cli>“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\u003C\u002Fli>\n\t\u003Cli>“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\u003C\u002Fli>\n\t\u003Cli>“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\u003C\u002Fli>\n\t\u003Cli>“Crocin also significantly improved International Index of Erectile Functions ....”\u003C\u002Fli>\n\t\u003Cli>“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the section of your webpage titled “Crocin &amp; Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin is … a potent … anti-inflammatory agent.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\u003C\u002Fli>\n\t\u003Cli>“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895170&amp;s=merchant-items&amp;sr=1-2):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895736&amp;s=merchant-items&amp;sr=1-1):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Posted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\u003C\u002Fli>\n\t\u003Cli>Posted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\u003C\u002Fli>\n\t\u003Cli>Posted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Randy F. Pack\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision Director\u003Cbr>\nHuman &amp; Animal Food Division II East\u003Cbr>\nBaltimore District Office\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Song Gao\n\nSaffron Health Sciences\n\n13 Dexter Rd\n\nE Brunswick, NJ 08816-2873\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS #615429\n\nNovember 18, 2021\n\nDear Dr. Gao;\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people1. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\n\n“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\n\n“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\n\n“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\n\n“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\n\nFrom the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\n\n“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\n\n“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\n\n“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\n\n“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\n\n“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\n\n“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\n\nFrom the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\n\n“The neuroprotective effects of crocin against stroke is the focus of this article.”\n\n“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\n\n“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\n\nFrom the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\n\n“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\n\no “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNFa), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\n\no “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\n\no “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\n\nFrom the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\n\n“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\n\n“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\n\n“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\n\nFrom the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\n\n“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\n\n“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\n\n“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\n\nFrom the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\n\n“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\n\n“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\n\n“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\n\n“Crocin also significantly improved International Index of Erectile Functions ....”\n\n“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\n\nOn your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\n\n“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\n\nOn your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\n\n“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\n\nFrom the section of your webpage titled “Crocin & Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\n\n“Crocin is … a potent … anti-inflammatory agent.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\n\n“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\n\n“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895170&s=merchant-items&sr=1-2):\n\n“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895736&s=merchant-items&sr=1-1):\n\n“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\n\nExamples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\n\nPosted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\n\nPosted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\n\nPosted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\n\nYour Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\n\nSincerely,\n\n\u002FS\u002F\n\nRandy F. Pack\n\nProgram Division Director\n\nDivision Director\n\nHuman & Animal Food Division II East\n\nBaltimore District Office\n\n___________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.","Saffron Health Sciences","saffron-health-sciences-615429-11182021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021","2026-10-26T08:09:52.649006+00:00","2021-11-30","615429","DrugsFood & Beverages","2022-02-15","Dr. Song Gao","2026-08-20T02:23:11.401+00:00","VIA UPS","2021-11-18",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":20,"letter_url":70,"updated_at":71,"action_type":23,"case_status":72,"posted_date":73,"marcs_cms_no":74,"product_type":75,"closeout_date":20,"issuing_office":63,"recipient_name":20,"body_fetched_at":76,"delivery_method":77,"recipient_title":20,"reference_number":20,"action_taken_date":78,"medical_device_id":20,"response_letter_date":20},241,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026\">Prime Sciences\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs Sold Over the Internet","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14500 N. Northsight Blvd, STE 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@prime-sciences.com\"> info@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prime-sciences.com\"> support@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 721805\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prime Sciences:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cagrilintide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\u003C\u002Fp>\u003Cul>\u003Cli>“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\u003C\u002Fli>\u003Cli>“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-R (10MG) (identified as Retatrutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\u003C\u002Fp>\u003Cul>\u003Cli>“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\u003C\u002Fli>\u003Cli>“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-S (10MG) (identified as Semaglutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic – Weight Loss Supplement.”\u003C\u002Fli>\u003Cli>“Semaglutide peptide therapy benefits include:\u003Cbr>o Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\u003Cbr>o Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\u003Cbr>o Reduces blood sugar levels to promote weight loss”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-T (10MG) (identified as Tirzepatide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\u003C\u002Fp>\u003Cul>\u003Cli>“Tirzepatide therapy benefits include:\u003Cbr>o A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\u003Cbr>o Stimulates the production of insulin to lower blood sugar\u003Cbr>o Reduces appetite by slowing the time it takes the stomach to empty”\u003C\u002Fli>\u003Cli>“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MAZDUTIDE (10MG)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide peptide therapy benefits include:\u003Cbr>o Weight Management\u003Cbr>􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\u003C\u002Fli>\u003Cli>“Improved metabolic health\u003Cbr>o Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\u003Cbr>o Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\u003Cbr>o Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BAC water\u003C\u002Fu>\u003Cbr>Your firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\u003C\u002Fp>\u003Cp>Your Prime Sciences products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPrime Sciences\n\n14500 N. Northsight Blvd, STE 100\n\nScottsdale, AZ 85260\n\nUnited States\n\ninfo@prime-sciences.com\n\nsupport@prime-sciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 721805\nPrime Sciences:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nDespite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\nExamples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nCagrilintide\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\n“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\n“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-R (10MG) (identified as Retatrutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\n“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\n“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\nGLP1-S (10MG) (identified as Semaglutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\n“Ozempic – Weight Loss Supplement.”\n“Semaglutide peptide therapy benefits include:\no Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\no Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\no Reduces blood sugar levels to promote weight loss”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-T (10MG) (identified as Tirzepatide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\n“Tirzepatide therapy benefits include:\no A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\no Stimulates the production of insulin to lower blood sugar\no Reduces appetite by slowing the time it takes the stomach to empty”\n“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\nMAZDUTIDE (10MG)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\n“Mazdutide peptide therapy benefits include:\no Weight Management\n􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\n“Improved metabolic health\no Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\no Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\no Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\nBAC water\nYour firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\nYour Prime Sciences products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Sciences","prime-sciences-721805-03312026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026","2026-10-26T08:09:44.094362+00:00","Issued","2026-04-07","721805","Drugs","2026-08-19T04:49:30.204+00:00","Via Email","2026-03-31",{"id":80,"raw":81,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":90,"fei_number":20,"letter_url":91,"updated_at":92,"action_type":23,"case_status":72,"posted_date":93,"marcs_cms_no":94,"product_type":75,"closeout_date":20,"issuing_office":63,"recipient_name":95,"body_fetched_at":96,"delivery_method":97,"recipient_title":20,"reference_number":98,"action_taken_date":99,"medical_device_id":20,"response_letter_date":20},1219,[82,83,84,63,85,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-27T04:00:00Z\">09\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flouisiana-state-university-health-science-center-irb-686088-09272024\">Louisiana State University Health Science Center IRB\u003C\u002Fa>","Institutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HFD-45-09-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Charles C. Coleman, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>IRB Chair\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Louisiana State University Health Science Center IRB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>433 Bolivar Street, Suite 206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Orleans\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA Ref. No.: 24-HFD-45-09-01\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Coleman:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between July 17, 2023, and July 26, 2023, of the Louisiana State University Health Science Center, New Orleans (LSUHSC) Institutional Review Board (IRB). Investigator Koffi A. Amegadje, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Amegadje presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s August 16, 2023, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s August 16, 2023, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and FDA regulations governing the protection of human subjects.\u003C\u002Fp>\n\n\u003Cp>We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. The IRB failed to conduct continuing review of research at intervals of not less than once per year [21 CFR 56.109(f)]\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In order to fulfill the requirements of the IRB regulations, the IRB is required to conduct continuing review of previously approved research at intervals appropriate to the degree of risk, but not less than once per year [21 CFR 56.109(f)].\u003C\u002Fp>\n\n\u003Cp>Specifically, the LSUHSC IRB failed to conduct continuing review of research at least once per year for the following FDA-regulated studies:\u003C\u002Fp>\n\n\u003Cp>a. On August 8, 2019, the LSUHSC IRB approved Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” at a convened meeting. Continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;was due by August 7, 2020. However, the IRB did not conduct continuing review for this study until August 19, 2020 (a lapse of IRB approval for 12 days). The next IRB continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was due by August 18, 2021. However, the IRB did not conduct continuing review for this study until October 22, 2021 (a lapse of IRB approval for 78 days). We note that during the second lapse in IRB approval, between August 19, 2021, and September 29, 2021, study activity was ongoing, including enrollment of two subjects at clinical sites, and clinical site protocol deviations occurred.\u003C\u002Fp>\n\n\u003Cp>b. On January 15, 2021, the LSUHSC IRB approved Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” at a convened meeting. Continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was due by January 14, 2022. However, the IRB did not conduct continuing review for this study until March 14, 2022 (a lapse of IRB approval for 59 days). The next IRB continuing review for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>was due by March 13, 2023. However, the IRB did not conduct continuing review for this study until April 28, 2023 (a lapse of IRB approval for 46 days).\u003C\u002Fp>\n\n\u003Cp>We acknowledge that the studies listed above for failure to conduct continuing review of research at intervals of not less than once per year were not included on the Form FDA 483 you received, and therefore your written response does not address this violation for these clinical studies.\u003C\u002Fp>\n\n\u003Cp>However, in your August 16, 2023, written response, you stated that between June 2020 and July 2021, there were three episodes when the KUALI system did not send Continuing Review reminders as scheduled (45, 30, and 15 days before the Continuing Review date), and the KUALI system has been functioning properly since August 2021. You stated that the KUALI system sent at least one reminder to each clinical investigator for most of the studies identified during the inspection. You also stated that the IRB manually identified studies requiring continuing review during the KUALI system failure, and the IRB notified clinical investigators by email; however, you also stated that all relevant studies might not have been identified. You stated that you revised the notification schedule to send alerts at 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that the IRB plans to take the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Performing random spot checks of renewal notification on a monthly basis\u003C\u002Fli>\n\t\u003Cli>Contacting the vendor with a “high priority ticket” if notifications issues are detected, and manual scheduling; and, if the issue is not resolved within 7 days, manually sending alerts until the issue is resolved\u003C\u002Fli>\n\t\u003Cli>Revision to your Standard Operating Procedure, SOP 3.02, to reflect the new notification schedule of 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details regarding how the IRB (as opposed to the clinical investigator) would ensure that the IRB will conduct continuing review of research within the required time interval. While a clinical investigator has a responsibility to ensure that an IRB will conduct continuing review and approval of their study [21 CFR 312.66], the IRB still must conduct continuing review of research within the required interval, as required under 21 CFR part 56.\u003C\u002Fp>\n\n\u003Cp>Failure of the IRB to conduct continuing review at intervals of not less than once per year raises concerns about the adequacy of the IRB’s oversight of ongoing research that the IRB had previously approved.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The IRB failed to prepare, maintain, and follow required written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and [the] Food and Drug Administration (FDA) [21 CFR 56.115(a)(6) and 56.108(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An IRB is required to prepare and maintain adequate documentation of IRB activities, including written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of any suspension or termination of IRB approval. The IRB must also follow such written procedures [21 CFR 56.108(b) and 56.115(a)(6)]. Furthermore, under 21 CFR 56.113, suspensions or terminations of IRB approval of FDA-regulated research must be reported promptly to the FDA.\u003C\u002Fp>\n\n\u003Cp>The IRB failed to adhere to these requirements. Specifically, the LSUHSC IRB’s written procedures fail to explicitly provide a procedure for reporting suspensions or terminations of IRB approval to the FDA. Additionally, the IRB failed to ensure that the suspension or termination of IRB approval for the following FDA-regulated studies was reported to the FDA:\u003C\u002Fp>\n\n\u003Cp>a. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on December 20, 2021.\u003Cbr>\nb. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on March 2, 2021.\u003Cbr>\nc. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on January 26, 2022.\u003Cbr>\nd. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on March 20, 2023.\u003Cbr>\ne. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on October 4, 2022.\u003Cbr>\nf. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on January 26, 2022.\u003Cbr>\ng. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on October 4, 2022.\u003Cbr>\nh. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on August 25, 2022.\u003C\u002Fp>\n\n\u003Cp>However, termination of IRB approval for the above-listed studies was not reported to the FDA.\u003C\u002Fp>\n\n\u003Cp>In your August 16, 2023, written response to the Form 483, you stated that the IRB failed to recognize administrative closures as instances of termination of IRB approval, and therefore did not take reporting actions as dictated by IRB policies and FDA regulations. You stated that the IRB plans to take the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Educating IRB administrative staff annually on suspension and termination of IRB approval and related reporting requirements\u003C\u002Fli>\n\t\u003Cli>Creating an SOP on reporting incidents to the FDA that is similar to the IRB’s SOP HRP-2.01, “Reporting Incidents to [the] Office of [for] Human Research Protections (OHRP)”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the IRB procedures you are proposing to develop, and how you will ensure that these proposed written procedures will be followed to prevent repeat violations. Without these details, we are unable to determine whether your corrective action plan is adequate to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure of the IRB to prepare, maintain, and follow required written procedures raises concerns about the adequacy of the IRB’s review processes for ensuring the protection of the rights, safety, and welfare of human research subjects.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or to the IRB’s review and approval of protocols. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the IRB has taken or plans to take, to address any violations and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the IRB has complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\u003C\u002Fp>\n\n\u003Cp>If the IRB has any questions, you may email FDA at CDER-OSICommunications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Brittany L. Garr-Colón, M.P.H.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(6)\u003C\u002Fstrong>, Chancellor\u003Cbr>\nLouisiana State University Health Science Center\u003Cbr>\n433 Bolivar Street, Suite 815\u003Cbr>\nNew Orleans, Louisiana 70112\u003Cbr>\nReference ID: 5453362\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n09\u002F27\u002F2024 11:03:55 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n24-HFD-45-09-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCharles C. Coleman, M.D.\n\nRecipient Title\n\nIRB Chair\n\nLouisiana State University Health Science Center IRB\n\n433 Bolivar Street, Suite 206\n\nNew Orleans, LA 70112\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nFDA Ref. No.: 24-HFD-45-09-01\n\nDear Dr. Coleman:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between July 17, 2023, and July 26, 2023, of the Louisiana State University Health Science Center, New Orleans (LSUHSC) Institutional Review Board (IRB). Investigator Koffi A. Amegadje, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\n\nThis inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Amegadje presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s August 16, 2023, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s August 16, 2023, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations governing the protection of human subjects.\n\nWe wish to emphasize the following:\n\n1. The IRB failed to conduct continuing review of research at intervals of not less than once per year [21 CFR 56.109(f)]\n\nIn order to fulfill the requirements of the IRB regulations, the IRB is required to conduct continuing review of previously approved research at intervals appropriate to the degree of risk, but not less than once per year [21 CFR 56.109(f)].\n\nSpecifically, the LSUHSC IRB failed to conduct continuing review of research at least once per year for the following FDA-regulated studies:\n\na. On August 8, 2019, the LSUHSC IRB approved Protocol (b)(4), “(b)(4),” at a convened meeting. Continuing review for Protocol (b)(4) was due by August 7, 2020. However, the IRB did not conduct continuing review for this study until August 19, 2020 (a lapse of IRB approval for 12 days). The next IRB continuing review for Protocol (b)(4) was due by August 18, 2021. However, the IRB did not conduct continuing review for this study until October 22, 2021 (a lapse of IRB approval for 78 days). We note that during the second lapse in IRB approval, between August 19, 2021, and September 29, 2021, study activity was ongoing, including enrollment of two subjects at clinical sites, and clinical site protocol deviations occurred.\n\nb. On January 15, 2021, the LSUHSC IRB approved Protocol (b)(4), “(b)(4),” at a convened meeting. Continuing review for Protocol (b)(4) was due by January 14, 2022. However, the IRB did not conduct continuing review for this study until March 14, 2022 (a lapse of IRB approval for 59 days). The next IRB continuing review for Protocol (b)(4) was due by March 13, 2023. However, the IRB did not conduct continuing review for this study until April 28, 2023 (a lapse of IRB approval for 46 days).\n\nWe acknowledge that the studies listed above for failure to conduct continuing review of research at intervals of not less than once per year were not included on the Form FDA 483 you received, and therefore your written response does not address this violation for these clinical studies.\n\nHowever, in your August 16, 2023, written response, you stated that between June 2020 and July 2021, there were three episodes when the KUALI system did not send Continuing Review reminders as scheduled (45, 30, and 15 days before the Continuing Review date), and the KUALI system has been functioning properly since August 2021. You stated that the KUALI system sent at least one reminder to each clinical investigator for most of the studies identified during the inspection. You also stated that the IRB manually identified studies requiring continuing review during the KUALI system failure, and the IRB notified clinical investigators by email; however, you also stated that all relevant studies might not have been identified. You stated that you revised the notification schedule to send alerts at 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date.\n\nIn your written response, you stated that the IRB plans to take the following corrective actions:\n\nPerforming random spot checks of renewal notification on a monthly basis\n\nContacting the vendor with a “high priority ticket” if notifications issues are detected, and manual scheduling; and, if the issue is not resolved within 7 days, manually sending alerts until the issue is resolved\n\nRevision to your Standard Operating Procedure, SOP 3.02, to reflect the new notification schedule of 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details regarding how the IRB (as opposed to the clinical investigator) would ensure that the IRB will conduct continuing review of research within the required time interval. While a clinical investigator has a responsibility to ensure that an IRB will conduct continuing review and approval of their study [21 CFR 312.66], the IRB still must conduct continuing review of research within the required interval, as required under 21 CFR part 56.\n\nFailure of the IRB to conduct continuing review at intervals of not less than once per year raises concerns about the adequacy of the IRB’s oversight of ongoing research that the IRB had previously approved.\n\n2. The IRB failed to prepare, maintain, and follow required written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and [the] Food and Drug Administration (FDA) [21 CFR 56.115(a)(6) and 56.108(b)(3)].\n\nAn IRB is required to prepare and maintain adequate documentation of IRB activities, including written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of any suspension or termination of IRB approval. The IRB must also follow such written procedures [21 CFR 56.108(b) and 56.115(a)(6)]. Furthermore, under 21 CFR 56.113, suspensions or terminations of IRB approval of FDA-regulated research must be reported promptly to the FDA.\n\nThe IRB failed to adhere to these requirements. Specifically, the LSUHSC IRB’s written procedures fail to explicitly provide a procedure for reporting suspensions or terminations of IRB approval to the FDA. Additionally, the IRB failed to ensure that the suspension or termination of IRB approval for the following FDA-regulated studies was reported to the FDA:\n\na. Protocol (b)(4) was administratively closed by the IRB on December 20, 2021.\n\nb. Protocol (b)(4) was administratively closed by the IRB on March 2, 2021.\n\nc. Protocol (b)(4) was administratively closed by the IRB on January 26, 2022.\n\nd. Protocol (b)(4) was administratively closed by the IRB on March 20, 2023.\n\ne. Protocol (b)(4) was administratively closed by the IRB on October 4, 2022.\n\nf. Protocol (b)(4) was administratively closed by the IRB on January 26, 2022.\n\ng. Protocol (b)(4) was administratively closed by the IRB on October 4, 2022.\n\nh. Protocol (b)(4) was administratively closed by the IRB on August 25, 2022.\n\nHowever, termination of IRB approval for the above-listed studies was not reported to the FDA.\n\nIn your August 16, 2023, written response to the Form 483, you stated that the IRB failed to recognize administrative closures as instances of termination of IRB approval, and therefore did not take reporting actions as dictated by IRB policies and FDA regulations. You stated that the IRB plans to take the following corrective actions:\n\nEducating IRB administrative staff annually on suspension and termination of IRB approval and related reporting requirements\n\nCreating an SOP on reporting incidents to the FDA that is similar to the IRB’s SOP HRP-2.01, “Reporting Incidents to [the] Office of [for] Human Research Protections (OHRP)”\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the IRB procedures you are proposing to develop, and how you will ensure that these proposed written procedures will be followed to prevent repeat violations. Without these details, we are unable to determine whether your corrective action plan is adequate to prevent similar violations in the future.\n\nFailure of the IRB to prepare, maintain, and follow required written procedures raises concerns about the adequacy of the IRB’s review processes for ensuring the protection of the rights, safety, and welfare of human research subjects.\n\nThis letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or to the IRB’s review and approval of protocols. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the IRB has taken or plans to take, to address any violations and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the IRB has complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nWe recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\n\nIf the IRB has any questions, you may email FDA at CDER-OSICommunications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\n\nBrittany L. Garr-Colón, M.P.H.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nCc: (b)(6), Chancellor\n\nLouisiana State University Health Science Center\n\n433 Bolivar Street, Suite 815\n\nNew Orleans, Louisiana 70112\n\nReference ID: 5453362\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n09\u002F27\u002F2024 11:03:55 AM","Louisiana State University Health Science Center IRB","louisiana-state-university-health-science-center-irb-686088-09272024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flouisiana-state-university-health-science-center-irb-686088-09272024","2026-10-26T08:09:16.257991+00:00","2024-10-08","686088","Charles C. Coleman, M.D.","2026-08-19T22:30:56.744+00:00","VIA UPS and Electronic Mail","24-HFD-45-09-01","2024-09-27",4,{"510k":102,"classification":103,"enforcement":104,"event":105,"event_backfill":106,"pma":107,"warning_letter":108},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]